NASACORT HFA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for NASACORT HFA (NASACORT HFA).
Corticosteroid that binds to glucocorticoid receptors, inhibiting inflammatory mediators (e.g., cytokines, prostaglandins) and reducing nasal inflammation.
| Metabolism | Primarily metabolized by CYP3A4 isoenzyme; undergoes first-pass metabolism in the liver. |
| Excretion | Renal (approximately 40% as metabolites), fecal (approximately 60% as metabolites and parent drug) |
| Half-life | Terminal elimination half-life is approximately 3.5 hours following intranasal administration, reflecting slow systemic absorption and prolonged local retention. |
| Protein binding | Approximately 71% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Volume of distribution is approximately 203 L (2.9 L/kg based on 70 kg body weight), indicating extensive tissue distribution. |
| Bioavailability | Absolute intranasal bioavailability is approximately 49%, due to partial absorption from the nasal mucosa and first-pass metabolism. |
| Onset of Action | Onset of clinical effect (symptom relief) typically occurs within 12 hours after the first intranasal dose, though maximal benefit may require several days. |
| Duration of Action | Duration of action is approximately 24 hours with once-daily dosing, allowing for sustained control of allergic rhinitis symptoms. |
55 mcg (1 spray) per nostril once daily; may increase to 110 mcg (2 sprays) per nostril once daily if needed. Maximum 440 mcg/day total.
| Dosage form | SPRAY, METERED |
| Renal impairment | No dose adjustment required. |
| Liver impairment | No dose adjustment required. |
| Pediatric use | 2-11 years: 55 mcg (1 spray) per nostril once daily; maximum 110 mcg (2 sprays) per nostril once daily. Children >=12 years: same as adult. |
| Geriatric use | No specific dose adjustment; use caution due to potential for increased systemic effects, but no dose reduction routinely recommended. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for NASACORT HFA (NASACORT HFA).
| Breastfeeding | It is not known whether triamcinolone acetonide is excreted in human milk; however, other corticosteroids are excreted. No M/P ratio available for intranasal triamcinolone acetonide. Caution should be exercised when administered to nursing mothers; lowest effective dose recommended. |
| Teratogenic Risk | No adequate and well-controlled studies in pregnant women. In animal studies, triamcinolone acetonide caused fetal toxicity (cleft palate, skeletal abnormalities) at doses ≥ 0.02 times the maximum recommended human intranasal dose (MRHID). Intranasal corticosteroids are generally considered low risk for teratogenicity when used at therapeutic doses, but first-trimester exposure should be minimized. Insufficient data for second and third trimesters; fetal growth may be affected with chronic high-dose systemic exposure. |
■ FDA Black Box Warning
No FDA boxed warning.
| Serious Effects |
["Hypersensitivity to triamcinolone acetonide or any component.","Untreated localized nasal infections (e.g., herpes simplex)."]
| Precautions | ["Risk of Candida albicans infection in nose and pharynx.","Nasal septal perforation (rare) with prolonged use.","Systemic corticosteroid effects (e.g., growth suppression in children, glaucoma, hypercorticism) when used at higher doses.","Immune suppression: Increased susceptibility to infections.","Avoid use in patients with recent nasal trauma, surgery, or ulcers."] |
Loading safety data…
| Fetal Monitoring | Monitor for signs of maternal adrenal suppression with prolonged high-dose use. Fetal growth and development should be assessed during routine prenatal visits; consider ultrasound if prolonged use of high doses. Neonates exposed in utero should be monitored for adrenal insufficiency if maternal dose was high. |
| Fertility Effects | Triamcinolone acetonide at systemic doses has been shown to impair fertility in animal studies (e.g., prolonged estrous cycle, reduced conception rates). No human data on fertility effects with intranasal use; effects are unlikely at recommended intranasal doses due to minimal systemic absorption. |